This is even more relevant considering the current trend of applying PSMA radioligand therapy for smaller tumors or earlier disease stages, such as hormone-sensitive PCa (NCT03828838, NCT04720157, NCT04297410, NCT04343885) [10, 12]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.